VRDN Q1 2020 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$828,000+122.6% YoY

Gross Profit

$828,000100.0% margin

Operating Income

-$8M-965.9% margin

Net Income

-$8M-971.5% margin

EPS (Diluted)

$-2.65

QoQ Revenue Growth

-5.9%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$664,000

Balance Sheet

Total Assets

$39M

Total Liabilities

$12M

Stockholders' Equity

$27M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$828,000	$372,000	+122.6%
Gross Profit	$828,000	-$8M	+109.9%
Operating Income	-$8M	-$12M	+31.9%
Net Income	-$8M	-$12M	+30.8%

Revenue Segments

Reimbursement Revenue

$700,000100%